Elan's once-daily naproxen (Naprelan)
Executive Summary
Syntex, marketer of the twice-daily branded naproxen product Naprosyn, acquires exclusive U.S. marketing rights to Elan's once- daily formulation. Naprelan "is in the final stages of clinical trials" in the U.S., the companies announce March 17, and an NDA for the nonsteroidal anti-inflammatory drug will be submitted to FDA "during the second half of calendar 1993".